Anbio Biotechnology (NASDAQ:NNNN) Shares Down 10.2% - Here's Why

Key Points

• Shares fell 10.2% on Wednesday, last trading at $26.23 after hitting a low of $26.40, with 37,933 shares changing hands (about 21% below the average session volume).
• Weiss Ratings downgraded Anbio from "hold (c-)" to "sell (d+)," and MarketBeat shows a consensus rating of "Sell."
• The company reported quarterly earnings of $0.03 per share, with the stock's 50-day moving average at $25.19.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report)'s share price traded down 10.2% on Wednesday . The stock traded as low as $26.40 and last traded at $26.23. 37,933 shares traded hands during trading, a decline of 21% from the average session volume of 48,034 shares. The stock had previously closed at $29.20.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Anbio Biotechnology from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, April 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Anbio Biotechnology currently has a consensus rating of "Sell".

Anbio Biotechnology Stock Performance

The stock's 50 day moving average is $25.19.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 7th. The company reported $0.03 earnings per share for the quarter.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.